So-Young (SY) Q4 2025 Earnings Call Transcript

So-Young reported record Q4 revenue of RMB 451 million, up 25% YoY, driven by aesthetic center revenue of RMB 248.1 million (+205% YoY) which now represents >50% of total revenue. Management operates 49 centers (10 net adds in the quarter), with 25 centers profitable and 39 generating positive operating cash flow, and plans to open at least 35 new centers in 2026; Q4 2026 aesthetic treatment services guidance is RMB 258–278 million (projected +171% to +181% YoY). Financially, net loss attributable to So-Young narrowed to RMB 108.8 million (from RMB 607.6m prior year) while non-GAAP net loss widened to RMB 93.4 million and cash/short-term investments fell to RMB 936.4 million (from RMB 1,253.2m), highlighting strong top-line scaling but ongoing profitability and liquidity considerations.

Analysis

So-Young’s unit-economics inflection is the core value lever: as branded clinics move from ramp to maturity they convert fixed-cost absorption, membership LTV and lower promo intensity into outsized incremental margin. That creates a predictable multi-quarter cadence — expect most delta to materialize within 12–24 months as current growth-phase centers mature and contribution mix shifts toward higher-margin services.

A rapid scaling procurement play is a second-order alpha source. Volume-linked pricing and exclusive product access can compress consumable cost per treatment materially, but supplier concentration and tighter upstream regulation (device approvals, distribution rules) create a vulnerability: favorable pricing today can flip to squeeze if regulators or suppliers change contracting economics.

Cash deployment and execution risk are the primary brakes. Management’s pivot to “growth with profitability” reduces binary expansion risk, yet the firm remains capital intensive and reliant on physician hiring, local licensing, and mall placement — any slippage in those operational inputs would pressure runway and re-rate the multiple in weeks to quarters.

Macro and competitive dynamics favor a national roll-up strategy: success in lower-tier cities signals a replicable model that attracts private capital and incumbents, raising both consolidation and M&A optionality. Near-term catalysts to watch are: sequential margin improvement from procurement, retention metrics for core members, and any regulatory or supplier-contract headlines that could reverse the tailwind.

Key Decisions for Investors

• Long SY (So‑Young ADS) — buy size = 1–2% of portfolio; horizon 12–18 months. Rationale: asymmetric upside from center maturation and procurement-driven margin expansion. Entry: initiate on any sub‑20% pullback post next quarterly release; target +60–100% upside, hard stop at −35% to limit balance‑sheet / execution risk.
• Options: bullish call spread on SY — buy 12‑18 month LEAP call and sell higher‑strike call to finance (~30–50% OTM buy / 90–120% OTM sell depending on market). Horizon 12–18 months. Rationale: levered exposure to margin inflection with capped capital at known cost; worst-case limited premium loss if execution falters.
• Event hedge: buy 3‑month SY puts as insurance around the next earnings/guidance print (size 0.2–0.5% portfolio). Rationale: protects against a sharp de‑rating if cash runway or regulatory inspection headlines emerge. Cost is insurance premium; treat as tactical risk management.
• Thematic: small tactical long DIS (Disney) exposure — size 0.5–1% portfolio; horizon 9–12 months. Rationale: IP co‑branding lifts CAC efficiency and experiential conversion; DIS is low‑cost way to express upside in branded consumer experiences tied to partnerships if So‑Young scales brand campaigns successfully. Cut if co‑branding cadence stalls or CAC rises materially.